Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer  by Le Jan, Sébastien et al.
FEBS Letters 580 (2006) 3395–3400Characterization of the expression of the hypoxia-induced genes neuritin,
TXNIP and IGFBP3 in cancer
Se´bastien Le Jana,b, Nolwenn Le Meurc,d, Aure´lie Cazesa,b, Josette Philippea,b,
Martine Le Cunﬀc,d, Jean Le´gerc,d, Pierre Corvola,b, Ste´phane Germaina,b,e,*
a INSERM, Unit 36, F-75005 Paris, France
b Colle`ge de France, F-75005 Paris, France
c INSERM, Unit 533, F-44000 Nantes, France
d Universite´ de Nantes, Faculte´ de Me´decine, F-44000 Nantes, France
e AP-HP, Hoˆpital Europe´en Georges Pompidou, Service d’He´matologie Biologique A, Paris, France
Received 28 March 2006; revised 27 April 2006; accepted 3 May 2006
Available online 11 May 2006
Edited by Robert BaroukiAbstract By triggering an adaptive response to hypoxia which is
a common feature of tumor microenvironments, endothelial cells
contribute to the onset of angiogenic responses involved in tumor
growth. Therefore, identifying hypoxic markers represent a chal-
lenge for a better understanding of tumor angiogenesis and for the
optimization of anti-angiogenic therapeutic strategy. Using rep-
resentational diﬀerence analysis combined with microarray, we
here report the identiﬁcation of 133 hypoxia-induced transcripts
in human microendothelial cells (HMEC-1). By Northern blot,
we conﬁrm hypoxia-induced expression of insulin-like growth
factor binding protein 3 (igfbp3), thioredoxin-interacting protein
(txnip), neuritin (nrn1). Finally, by performing in situ hybridiza-
tion on several types of human tumors, we provide evidence for
nrn1 and txnip as hypoxic perinecrotic markers and for igfbp3
as a tumor endothelial marker. We propose these hypoxia-in-
duced genes could represent relevant prognostic tools and targets
for therapeutic intervention in cancers.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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By exercising control over gene transcription, hypoxia is a
common feature of several human pathologies, including car-
diovascular diseases and cancer. In solid tumors, the balance
between cell proliferation and oxygen supply is aﬀected, lead-
ing to a decrease in oxygen partial pressure (pO2) [1]. Hypoxic
cells trigger an adaptative molecular response to modulate
expression of many genes in order to allow better perfusion
and (pO2) increase in tumor tissue. Hypoxia-induced gene
expression is under the control of key-transcription factors,
the hypoxia-inducible factors (HIFs) [2], involving posttransla-
tional modiﬁcations of the a-subunit which determine both
half-life and transcriptional activity on target genes [3,4].Abbreviations: HMEC-1, human microendothelial cells 1; IGFBP3,
insulin-like growth factor binding protein 3; TXNIP, thioredoxin-
interacting protein; NRN1, neuritin
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doi:10.1016/j.febslet.2006.05.011Angiogenesis promotes not only tumor growth, but also
progression from a pre-malignant to a malignant and invasion
tumor phenotype. In the tumor microenvironment, hypoxia
appears to target a multiplicity of cell types which participate
in tumor progression and endothelial cells are widely involved
in tumor angiogenesis. In this context, targeting the tumor vas-
culature to ‘‘normalize’’ it [5] temporarily or to eradicate it
completely seems to be a promising anti-cancer-therapeutic
strategy [6]. To this aim, gene expression proﬁles of tumor cells
[7] but also of endothelial cells in response to hypoxia were
characterized by using microarray technologies or diﬀerential
screening techniques [8–11]. However, new markers are needed
for a better understanding of the hypoxia-induced angiogene-
sis in tumors and for the development of new diagnostic, prog-
nostic and therapeutic tools in cancer [8].
Here, we ﬁrst report a novel repertoire of hypoxia-induced
transcripts (HITs) in human microendothelial cells (HMEC-1)
using mRNA diﬀerential screening by cDNA representational
diﬀerence analysis (cDNA RDA) [12] and cDNA microarray.
We then described mRNA expression of HITs, particularly
neuritin (nrn1), thioredoxin-interacting protein (txnip) and
insulin-like growth factor binding protein 3 (igfbp3), in various
types of human tumors. Based on these observations, we there-
fore propose these HITs might represent relevant prognostic
tools and targets for therapeutical intervention in cancers.2. Material and methods
2.1. Cell culture and tissues
Primary cultures of HUVEC at passage 3 were cultured in EGM-2
medium (Cambrex) with 2% FBS and HMEC-1 (human dermal micro-
vascular endothelial cells, a gift from Thomas J. Lawley, Emory Uni-
versity, School of Medicine, Atlanta, GA) maintained as previously
described. For hypoxic treatments, cells were grown in an atmosphere
containing 2% O2, in an IG750 incubator (Jouan, France), or in the
presence of 100 lmol/L of DFO for 20 h.
All tumor tissues were obtained from the Pathological Anatomy
Department of Tenon Hospital (Paris, France). Tissues were ﬁxed in
20% formaldehyde and embedded in paraﬃn. Human tumors were
classiﬁed according to the revised World Health Organization criteria
for tumors.
2.2. RNA isolation and cDNA synthesis
Total RNA was isolated from HMEC-1 and HUVEC cultured in
hypoxic and normoxic conditions using the RNeasy midiprep kit from
Qiagen. RNA was digested with RNase-free DNase RQ1 (Promega)blished by Elsevier B.V. All rights reserved.
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Oligotex mRNA kit (Qiagen) procedures twice, were used to synthesize
double-stranded cDNA using oligodT priming and Superscript II
(Invitrogen).
2.3. cDNA representational diﬀerence analysis
Representational diﬀerence analysis of cDNAs was performed as de-
scribed previously [12] with several important modiﬁcations [13,14].
Subtracted RDA products were inserted into the pGEM-T cloning
vector (Promega) and analyzed by sequencing. Classiﬁcation of the
HITS was performed according to S.O.U.R.C.E. database [15].
2.4. Gene expression analysis
The cDNAmicroarray was constructed by combining both the HITs
obtained by the cDNA RDA and the cDNA library described by
Steenman et al. [16]. cDNA microarray construction and hybridization
was performed as in Steenman et al. [16]. Data were pre-processed with
MADSCAN [17]. To normalize intensity values the rank invariant
method was used [18]. This method selects invariant gene reporters
on which a non-linear regression method (lowess ﬁtness) is applied to
calculate the normalization correction factor [19]. The identiﬁcation
of genes with statistically signiﬁcant diﬀerential expression between
the two populations of cells was performed using the limma R package
[20]. False discovery rate (FDR) correction was applied to take into ac-
count multiple testing hypotheses. Signiﬁcance levels were set to
P < 0.05 and P < 0.01. Genes below these thresholds were considered
signiﬁcantly diﬀerentially expressed.
Northern blots were performed using NorthernMax kit from Am-
bion. Brieﬂy, 20 lg/lane of total RNA was fractionated by 1% denatur-
ing gel electrophoresis and transferred to nylon membranes (Hybond
N+; Amersham Biosciences). The blots were hybridized with 32P-la-
beled cDNA probes (Random Primer DNA Labeling System; Invitro-
gen) overnight at 42 C in the UltraHyb solution (Ambion). Paraﬃn
section preparation, probe labeling by in vitro transcription, and
in situ hybridization were performed as previously described [14].
2.5. Immunohistochemistry
Immunostaining with a polyclonal goat anti-human IGFBP3 (1/50;
R&D Systems AF675) antibody was performed by routine methods
using a biotinylated secondary antibody and the ABC-peroxidase com-
plex (Vector Laboratories) with diaminobenzidine-H2O2 used as the
chromogen for detection.Fig. 1. Conﬁrmation of cDNA microarray by Northern blot analysis.
Total RNA from HMEC-1 and HUVEC cultured in normoxia or
hypoxia (100 lMDFO or 2% O2) were fractionated on a formaldehyde
agarose gel, transferred to a nylon membrane and probed with 32P-
labeled probes for igfbp3, nrn1, txnip and angptl4 mRNAs.3. Results and discussion
In order to identify genes whose expression is induced by hy-
poxia in endothelial cells, we performed a diﬀerential screening
by cDNA representational diﬀerence analysis between HMEC-
1 cells, the ﬁrst immortalized endothelial cells which retains the
main characteristics of primary endothelial cells, cultured in
normoxia (20% O2) or in the presence of the iron chelator des-
feroxamine, thus mimicking hypoxia for 20 h. Both normoxic
and hypoxic cDNA libraries are prepared and three successive
rounds of hybridization/PCR ampliﬁcation were performed
allowing to obtain cDNAs which are overexpressed in hypoxia
compared to normoxia. 1000 clones were subsequently se-
quenced and 300 non-redundant cDNA fragments were identi-
ﬁed. These HITs were used for creating a cDNA microarray
slide which was then hybridized with cDNAs from HMEC-1
cultured either in chemical (DFO 100 lM), gaseous (2% O2)
hypoxia or normoxia for 20 h. The data were subjected to sta-
tistical analysis allowing the identiﬁcation of 131 genes overex-
pressed in endothelial cells (ECs) cultured under chemical
hypoxia, of which 57 are also induced by gaseous hypoxia
(see supplementary material, Table 1). Seventy-seven percent
were annotated genes and 23% left were ESTs or hypothetical
proteins. Classiﬁcation of RDA-induced genes according toS.O.U.R.C.E. conﬁrmed most cellular functions are regulated
by hypoxia. Indeed, consistent with previous observations, we
observed the increased expression of genes which are involved
in cellular metabolism, including glycolysis genes (tpi1, g3pdb,
hk2, eno1, ldha) and glucose transporters (glut3). We further
conﬁrmed a large number of genes, such as txnip, igfbp3 and
angptl4, which have already been shown to be overexpressed
in primary endothelial cell lines as HUVECs, HAECs and
HPAECs in previous transcriptome studies using various ap-
proaches [8–11]. Interestingly, we provided evidence for new
endothelial HITs such as neuritin, neuroleukin, stk25, csnk1e
and snrk, plectin and cortactin involved in neurogenesis/neu-
ritogenesis, signal transduction and cytoskeletal organisation,
respectively.
In order to further conﬁrm hypoxia induction, we performed
Northern blot analysis on HMEC-1 and HUVEC cultured in
hypoxic conditions, speciﬁcally for the pro-apoptotic gene
igfbp3, the tumor and metastasis suppressor gene txnip and
the ﬁrstly described hypoxia-induced gene neuritin1 (nrn1).
Normalization of the genes of interest to a housekeeping gene,
such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
b-actin or cyclophilin could not be performed here since the fact
that steady-state levels of these control genes cannot be as-
sumed in endothelial cells exposed to DFO or 2% hypoxia.
Therefore, the amounts of RNA loaded were normalized by
hybridization with a 28S-speciﬁc probes which is known to be
a constant fraction of total RNA. We observed hypoxia-
induced expression of these 3 genes in both endothelial cell
types, namely HMEC-1 and HUVEC, subjected to chemical
hypoxia compared to normoxia, as previously shown for ang-
ptl4 [14], used as a control here. Lowering oxygen concentration
also induced expression of igfbp3 and nrn1 in both HMEC-1
and HUVEC while level of expression was less important than
using DFO. Txnip mRNA was not detected in HUVEC and
only very weakly in HMEC-1 cells cultured in gaseous hypoxic
conditions (Fig. 1). DFO as an iron chelator used at 100 lM
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and FIH inactivation andmight enhance transcription via HIF-
a, which could explain diﬀerences between chemical and gas-
eous hypoxia-induced gene expressions. HIF-prolylhydroxy-
lases (PHD1-3) and factor inhibiting HIF (FIH) are enzymes
belonging to 2-oxoglutarate and Fe(II) dependent dioxygenases
superfamily. They are involved in HIF-a proteasome degrada-
tion and transcription suppression by hydroxylation of oxygen-
dependent degradation domain (ODDD) and C-terminal trans-
activation domain (C-TAD), respectively, and have iron (Fe2+),
2-oxoglutarate and dioxygen as co-substrates [4].
Given that both tumor and vascular cells were shown to be
hypoxic in tumors, we then studied the expression of these
HITs in various types of human cancers with the aim to char-
acterize new tumor and/or tumor endothelial markers. In the
present study, we focused on nrn1, txnip and igfbp3 for which
no or only few data were available concerning their in situ
mRNA expression in cancers.
Neuritin, also called CPG15, is a GPI-anchored protein
which was reported to be weakly expressed in human kidney,
heart, spleen, lung [21]. Neuritin is also expressed in the liver
and is well correlated to the maturation of hepatocytes [22]
as well as in neuronal structures associated with plasticity in
the adult [21]. NRN1 has been largely involved in neuritogen-
esis and was shown to promote dendritic growth [23] and theFig. 2. Nrn1 and Txnip, markers of perinecrotic regions in conventional RC
views of nrn1 and txnip mRNA production in perinecrotic region of conven
respectively). N, necrosis area. Scale bars, 50 lm.development of motor neuron axon arbors [24]. In this study,
we demonstrated that nrn1 gene is expressed and induced by
hypoxia in ECs. Neuritin could therefore belong to the increas-
ing family of axon guidance which could be implicated in ves-
sel pathﬁnding and network formation as recently shown for
several of these molecules [25]. To the best of our knowledge,
nrn1 mRNA expression has never been described in human
biopsies from normal or tumor tissues. Here, by performing
in situ hybridization experiments, we examined nrn1 mRNA
expression in diﬀerent human tumors such as colon and pros-
tate tumors, renal cell carcinoma and glioblastoma. Nrn1 is ex-
pressed in both tumor and normal epithelial cells and weakly
in endothelia of blood vessels of normal and tumoral areas
in colon and prostate (data not shown). For the ﬁrst time,
we showed that nrn1 mRNA is reproducibly highly expressed
in a restricted number of tumor cells around perinecrotic re-
gions of conventional RCC (Fig. 2a–c) and glioblastoma
(Fig. 2d–f), regions in which hypoxia has been reported to
upregulate gene expression [26]. We did not detect nrn1 expres-
sion in peritumoral areas of these two types of tumor (data not
shown). Furthermore, NRN1 has recently been implicated in
tumorigenesis by promoting changes in cell morphology,
anchorage-independent growth and tumor formation [27]. In
this context, the fact that hypoxic tumor cells highly express
neuritin makes this molecule an attractive candidate as aC and glioblastoma. Bright ﬁeld (left and right) and dark ﬁeld (middle)
tional RCC (a–c and g–i, respectively) and glioblastoma (d–f and j–l,
3398 S. Le Jan et al. / FEBS Letters 580 (2006) 3395–3400hypoxic tumor marker and a potential target for therapeutic
intervention in cancers.
Thioredoxin-interacting protein is interacting and nega-
tively regulating thioredoxin [28] and is involved in suppres-
sion of tumor growth [29]. Furthermore, in an in vitro
model of intravasation, overexpression of TXNIP by infect-
ing melanoma cells with adenovirus increased transendothe-
lial migration 3-fold versus control [30]. Until now, txnip
mRNA was reported to be downregulated in various human
tumors, including breast, stomach and lung [29] and gastroin-
testinal cancers [31]. For the ﬁrst time, we provide evidence
for txnip overexpression in tumor cells of hypoxic perine-
crotic areas of conventional RCC (Fig. 2g–i) and glioblas-
toma (Fig. 2j–l) compared to non-hypoxic tumor cells and
peritumoral tissues. Furthermore, hypoxia is often associated
with increased metastasis and poor prognosis in cancer.
Therefore, txnip might represent a valid candidate as prog-
nostic marker and therapeutic target for anti-metastatic
treatment.
We also studied IGFBP3 expression, which is shown to have
anti-IGF-1 and IGF-1-independent pro-apoptotic activities.
Many studies have provided evidence for the in vitro induction
of igfbp3 mRNA by hypoxia in diﬀerent cell types, including
ES cells [32], tumor cells [7,33] and ECs [9,11,34]. In vivo, a
marked increase of igfbp3mRNA was reported in the endothe-Fig. 3. Igfbp3 mRNA, a tumor endothelial marker in various types of human
igfbp3 mRNA expression in endothelial cells of colon adenocarcinoma
chromophobe RCC (j–l). Scale bars, 50 lm.lium of human corpus luteum during early phase of luteal
development which is accompanied by extensive angiogenesis
[35] and speciﬁcally in tumor endothelial cells of a murine
breast cancer model [36]. We here provide evidence for an
igfbp3 mRNA expression in intratumoral ECs of colon carci-
noma (Fig. 3a–c), whereas tumor and normal epithelial cells
of the colon do not express igfbp3 mRNA (data not shown).
Concerning prostate, we showed that igfbp3 is also very highly
expressed in the ECs of adenocarcinoma (Fig. 3d–f). We also
demonstrated that igfbp3 mRNA is speciﬁcally produced by
ECs of tumor blood vessels in conventional RCC classiﬁed as
pT1 in tumor, node, metastasis (TNM) system. In contrast,
to draw a conclusion from results obtained in patients with
pT2 and pT3 conventional RCC is more diﬃcult. Indeed,
igfbp3 mRNA is produced only by tumor cells in some patients
whereas expressed by both tumor cells and intratumor ECs in
some other patients (data not shown). Finally, igfbp3 mRNA
expression was investigated in chromophobe RCC. Accord-
ingly, a very high level of igfbp3 mRNA was observed only in
ECs of tumor vessels, but not in tumor cells, of all patients with
chromophobe RCC (Fig. 3j–l). Interestingly, igfbp3 mRNA
was not detected in peritumoral kidney of any renal tumor
(data not shown). We further characterized IGFBP3 protein
expression in these tumors by immunohistochemistry. IGFBP3
was detected in ECs of tumor vessels, but neither in tumor cellstumors. HES (left), dark ﬁeld (middle) and bright ﬁeld (right) views of
(a–c), prostate adenocarcinoma (d–f), conventional RCC (g–i) and
Fig. 4. Characterization of IGFBP3 protein expression in human
tumors. Immunostaining for IGFBP3 protein in conventional (a) and
chromophobe (b) RCC, in colon and prostate adenocarcinoma (c and
d, respectively). Scale bars, 50 lm.
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chromophobe RCC (Fig. 4a and b, respectively). These results
are in accordance with previous in vitro study showing a very
weak expression in primary proximal tubular cells and primary
renal cell carcinoma [37]. IGFBP3 is also expressed in peritu-
moral ECs of these tumors and in some tumor cells of chromo-
phobe RCC. We further demonstrated a similar pattern of
IGFBP3 staining in blood vessels of colon and prostate tumors
(Fig. 4c and d, respectively), with a high expression level in
both tumor endothelium as well as in peritumoral ECs close
to the tumor. We therefore characterize igfbp3 gene as an endo-
thelial marker in various human tumors. Recently, it was
shown that IGFBP3 reverses proliferation and prevents the
survival induced by VEGF in HUVEC [38] and that downreg-
ulation of endothelial igfbp3 mRNA by Runx1 transcription
factor promoted angiogenesis in the matrigel assay [39]. How-
ever, IGFBP3 functions in tumor-associated angiogenesis are
not understood yet and have to be examined thoroughly in or-
der to evaluate IGFBP3 suitability as a valid therapeutic target.
The present study compared nrn1, txnip and igfbp3 mRNAs
expression in tumor and peritumoral area. Data concerning
the expression of these genes in human biopsies from normal
organs (kidney, colon, prostate) are lacking in the literature.
Therefore, more detailed gene expression analyses have to be
performed on normal tissues to fully consider nrn1, txnip and
igfbp3 as proper tumor markers.
Altogether, this work provided evidence for a new set of hy-
poxia-induced genes in ECs in vitro. Overexpression of some
of these genes was further observed in diﬀerent cell types sub-
jected to in vivo pathological hypoxia, particularly in tumor
cells surrounding necrotic regions or tumor endothelial cells.
In this context, we propose these genes, txnip, nrn1 and igfbp3
as hypoxic markers and potential makers in tumor angiogene-
sis, might become prognostic tools and potential anti-cancer-
ous therapeutic targets.
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